Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
September 26, 2022 17:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical’s Rencofilstat to Treat Alcohol-Related Liver Disease
September 14, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
September 12, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional Biomarkers - - F3 NASH Subjects will be Evaluated...
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial
August 31, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Hepion Screens First Subject in Biopsy-Confirmed F2/F3 NASH Study - - Subjects will be Evaluated on Three Doses of Rencofilstat for a One-year Period - EDISON, N.J., Aug. 31, 2022 (GLOBE...
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders
July 22, 2022 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
June 28, 2022 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
June 24, 2022 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
June 20, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
June 15, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc....